Caracterización clínica de pacientes con Hepatitis autoinmune atendidos en una institución de salud de la Región Caribe colombiana

dc.contributor.advisorOrtega Quiroz, Orlando José
dc.contributor.advisorMaestre Serrano, Ronald Yesid
dc.contributor.authorEstrada Redondo, Cielo María
dc.coverage.spatialBarranquillaspa
dc.creator.emailcimaesre@hotmail.comspa
dc.date.accessioned2020-02-17T20:08:41Z
dc.date.available2020-02-17T20:08:41Z
dc.date.created2019
dc.description.abstractIntroducción: La hepatitis autoinmune (HAI) es una enfermedad hepática crónica inmunomediada poco común, que se caracteriza por hipergamaglobulinémia, autoanticuerpos circulantes, asociación al HLA, hepatitis de interfase en la histología y una respuesta favorable a inmunosupresión. En Latinoamérica existen pocos estudios epidemiológicos y es escasa la literatura a nivel nacional. Esta entidad es ahora reconocida porque afecta todos los grupos etarios, tiene gran asociación con el género femenino, oscilando clínicamente en su presentación desde pacientes asintomáticos hasta una falla hepática fulminante o cirrosis. El diagnóstico de hepatitis autoinmune es clínico patológico y el tratamiento se basa en la asociación de un corticoide y un inmunosupresor. Objetivo: Describir las características demográficas, clínicas y de laboratorio en pacientes con diagnostico HAI, en una institución de Salud de la ciudad de Barranquilla, Colombia. Metodología: Estudio descriptivo, retrospectivo, transversal, en el cual se analizaron historias clínicas de pacientes diagnosticados con hepatitis autoinmune mayores de 18 años de edad, durante el periodo del 01 agosto de 2012 al 31 enero de 2019, en una institución de Salud de la ciudad de Barranquilla, Colombia. Para el análisis estadístico se empleó el paquete estadístico SPSS versión 19. Resultados: Se analizaron 92 historias clínicas de pacientes de los cuales 85,9% eran mujeres y 14,1% hombres, con edad media 51 años. La forma de inicio fue aguda tipo hepatitis con presencia de ictericia en un 38% y el 14,1% fueron asintomáticos. A nivel paraclínico predomino hipergammaglobulinémia, elevación de aminotrasferasas, positividad de anticuerpos relacionados y una histología típica, incluyendo cirrosis en un 60,9% de los casos. Conclusión: La HAI no es un diagnóstico raro en nuestro medio y al igual que en la población mundial predomina en mujeres en su quinta y sexta década de la vida, con una presentación clínica variable, asociada con cirrosis en más de la mitad de los casos. Es imperativo la realización un diagnóstico oportuno y de esta forma realizar un plan terapéutico eficaz que permita la remisión completa y evite la progresión de la enfermedad.spa
dc.description.abstractBackground: Autoimmune hepatitis (AIH) is uncommon immune-mediated chronic liver disease, characterized by hypergammaglobulinaemia, circulating autoantibodies, association with HLA, interface hepatitis on liver histology and favourable response to immunosupression. In Latin America there are no clear epidemiological data and there are few studies at the national level; This entity is now recognized because it affects all age groups, and because it has a great association with the female gender, it clinically ranges from asymptomatic patients to fulminant hepatic failure or liver cirrhosis. The diagnosis of autoimmune hepatitis is clinically pathological and the treatment is based on the association of a corticoid and an immunosuppressant. Objective: describe the demographic, clinical, and laboratory characteristics of clinical records of patients diagnosed with AIH, in a health institution in the city of Barranquilla, Colombia. Metodology: A descriptive, retrospective, cross-sectional study, in which clinical histories of patients diagnosed with autoimmune hepatitis older than 18 years of age were analyzed during the period from August 1, 2012 to January 31, 2019, in a health institution of the city ??of Barranquilla, Colombia. For the statistical analysis, the statistical package SPSS version 19 was used. Results: We analyzed 92 clinical records of patients of which 85.9% were women and 14.1% men, with a mean age of 51 years. The form of onset was acute hepatitis type, with the presence of jaundice in 38%, although 14.1% were asymptomatic. At the paraclinical level, hypergammaglobulinemia, high aminotransferases levels, positivity of related antibodies, and typical histology, as well as cirrhosis in 60.9% of cases. Conclusion: AIH is not a rare diagnosis in our environment, as in the world population it predominates in women in their fifth and sixth decade of life, in addition to remaining with a variable clinical presentation, and cirrhosis association in more of half of the cases. It is imperative to carry out an opportune diagnosis and in this way an effective therapeutic plan that allows the complete remission and prevents the progression of the disease.Eng
dc.formatPDFspa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad Librespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Librespa
dc.identifier.urihttps://hdl.handle.net/10901/17899
dc.language.isospa
dc.relation.referencesJames S. Dooley et al. Sherlock’s diseases of the liver and biliary system. 12th ed. Wiley Blackwell A John Wiley & Sons, Ltd., Publication. 2011spa
dc.relation.referencesCzaja AJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Elsevier Health 2015, 1493-1511spa
dc.relation.referencesCzaja AJ. Diagnosis and Management of Autoimmune Hepatitis. MD Clin Liver Dis 2015;19: 57–79.spa
dc.relation.referencesCzaja AJ. Global disparities and their implications in the occurrence and outcome of autoinmune hepatitis. Digestive Diseases and Sciences. 2017;62:2277–2292spa
dc.relation.referencesJason W. Wen, Michael A. Kohn, et al. Hospitalizations for autoinmune hepatitis disproportionately affect black and latino americans. Am J Gastroenterol 2018; 113: 243 253.spa
dc.relation.referencesSebode, M., Hartl, J., Vergani, D., y Lohse, AW. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver international. 2018;38:15 22.spa
dc.relation.referencesSchmeltzer, PA, y Russo, MW. Clinical narrative: hepatitis autoinmune. The American Journal of Gastroenterology. 2018;113:951–958spa
dc.relation.referencesWebb, GJ, Rana, A., Hodson, J., Akhtar, MZ, Ferguson, JW, Neuberger, et al. Twenty year comparative analysis of patients with autoinmune liver disease on transplant waitlist. Clinical Gastroenterology abd Hepatology 2018;16:278-287spa
dc.relation.referencesDhruv Lowe, Savio John. Autoimmune hepatitis: Appraisal of current treatment guidelines. World J Hepatol. 2018;10(12):911-923spa
dc.relation.referencesMieli-Vergani, G., Vergani, D., Czaja, A. J., Manns, M. P., at el. Autoimmune hepatitis. Nature Reviews Disease Primers. 2018;4: 18017.1-17spa
dc.relation.referencesAl-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. Journal Hepatol. 2008;48(1):140-147.spa
dc.relation.referencesCzaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:2051–2057spa
dc.relation.referencesTiniakos, DG, Brain, JG, & Bury, YA. Role of histopathology in autoinmune hepatitis. Digestive Disease 2015;33(2):53–64.spa
dc.relation.referencesTerziroli Beretta-Piccoli, B., Mieli-Vergani, G., & Vergani, D. Serology in autoimmune hepatitis: A clinical-practice approach. European Journal of Internal Medicine. 2017;48:35–43spa
dc.relation.referencesGoldberg AC, Bittencourt PL, Oliveira LC, Ramasawmy R, MarinMLC, Palacios SA, et al. Autoimmune hepatitis in Brazil: Anoverview. Scand J Immunol. 2007;66(2-3):208-216spa
dc.relation.referencesDuarte-Rey C, Pardo AL, Rodríguez-Velosa Y, Mantilla RD, AnayaJM, Rojas-Villarraga A. HLA class II association with autoinmune hepatitis in Latin America: A metaanalysis. Autoimmun Rev.2009;8:325-331.spa
dc.relation.referencesDíaz-Ramírez, G. S., Marín-Zuluaga, J. I., Donado-Gómez, J. H., Muñoz-Maya, O., Santos-Sánchez, Ó., & Restrepo-Gutiérrez, J. C. Caracterización de los pacientes con hepatitis autoinmune de un hospital universitario, Medellín-Colombia: estudio de cohorte. Gastroenterología y Hepatología, 2018;41(2):87–96spa
dc.relation.referencesLondoño MC, Gonzalez LA, Chavarriaga JC, Munera V, RamosF, Suarez LD, et al. Aplicación del modelo diagnóstico del grupo internacional para la hepatitis autoinmune (GIHA) en una población de pacientes de Medellín, Colombia. Rev Colomb Gastroenterol. 2003;18:16-19spa
dc.relation.referencesJohnson PJ, McFarlane IG. Informe de la reunión: Grupo Internacional de Hepatitis Autoinmune. Hepatology 1993;18:998.spa
dc.relation.referencesWerner M, Prytz H, Ohlsson B, y col. Epidemiología y la presentación inicial de la hepatitis autoinmune en Suecia: un estudio a nivel nacional. Scand J Gastroenterol 2008;43:1232spa
dc.relation.referencesNgu JH, Bechly K, Chapman BA, y col. Estudio epidemiológico basado en la población de la hepatitis autoinmune: ¿una enfermedad de las mujeres mayores? J Gastroenterol Hepatol 2010;25:1681spa
dc.relation.referencesPrimo J, Maroto N, Martínez M, et al. Incidencia de la forma adulta de hepatitis autoinmune en Valencia (España). Acta Gastroenterol Belg 2009; 72: 402spa
dc.relation.referencesDe Boer, Y. S. et al. estudio de asociación de todo el genoma identifica variantes asociadas con hepatitis autoinmune de tipo 1. Gastroenterología 2014;147:443-452.e5.spa
dc.relation.referencesAlvarez, F. et al. Hepatitis autoinmune Internacional Informar del grupo: revisión de los criterios para el diagnóstico de la hepatitis autoinmune. J. Hepatol. 1999;31:929-938.spa
dc.relation.referencesDonaldson, P. T. Genética de la enfermedad hepática: inmunogenética y patogénesis de la enfermedad. Intestine. 2004;53:599-608.spa
dc.relation.referencesCzaja, A. J. & Donaldson, susceptibilidades P. T. genéticos para la expresión inmune y la lesión de células de hígado en la hepatitis autoinmune. Immunol. Rdo. 2000;174:250-259spa
dc.relation.referencesGregorio, G. V. et al. hepatitis autoinmune en la infancia: Una experiencia de 20 años. Hepatology. 1997;25:541-547.spa
dc.relation.referencesElfaramawy, A. A. M., Elhossiny, R. M., Abbas, A. A. Y Aziz, H. M. A. HLA-DRB1 como factor de riesgo en niños con hepatitis autoinmune y su relación con la hepatitis A infección. Ital. J. Pediatr.2010;36:73.spa
dc.relation.referencesPando, M. et al. formas pediátricas y adultas de tipo I hepatitis autoinmune en Argentina: La evidencia de predisposición genética diferencial. Hepatology. 1999;30:1374-1380.spa
dc.relation.referencesFainboim, L. et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001; 33:1512–1517spa
dc.relation.referencesUnderhill, J. A. et al. Different immunogenetic background in autoimmune hepatitis type 1, type 2 and autoimmune sclerosing cholangitis. J. Hepatol. 2002;36:156spa
dc.relation.referencesSimmonds, M. J. & Gough, S. C. L. Genetic insights into disease mechanisms of autoimmunity. Br. Med. Bull. 2004;71:93–113.spa
dc.relation.referencesListon, A., Lesage, S., Gray, D. H. D., Boyd, R. L. & Goodnow, C. C. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol. Rev. 2005;204:87–101.spa
dc.relation.referencesAhonen, P., Myllärniemi, S., Sipilä, I. & Perheentupa, J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med.1990;322:1829–1836.spa
dc.relation.referencesMuratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009;104:1420spa
dc.relation.referencesYuksel, M. et al. A novel ‘humanized mouse’ model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology. 2015;62:1536–1550.spa
dc.relation.referencesLin, R., Zhou, L., Zhang, J. & Wang, B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int. J. Clin. Exp. Pathol. 2015;8:5153–5160.spa
dc.relation.referencesVergani, D., Choudhuri, K., Bogdanos, D. P. & Mieli-Vergani, G. Pathogenesis of autoimmune hepatitis. Clin. Liver Dis. 2002;6:727–737.spa
dc.relation.referencesMackie, F. D. et al. Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 1994;106:1672–1675.spa
dc.relation.referencesBogdanos, D. P. et al. P0295 virus-self crossreactivity inducing de novo autoimmune hepatitis eight-years after liver transplantation. J. Pediatr. Gastroenterol. Nutr. 2004;39:S169.spa
dc.relation.referencesDelneste, Y. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood 2002;101:143–150.spa
dc.relation.referencesLonghi, M. S., Ma, Y., Mieli-Vergani, G. & Vergani, D. Regulatory T cells in autoimmune hepatitis. J. Hepatol. 2012;57:932–933.spa
dc.relation.referencesLiberal, R. et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology 2015;62:863–875.spa
dc.relation.referencesJohnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatol Baltim Md 1993;18:998–1005.spa
dc.relation.referencesHennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatol Baltim Md 2008;48:169–176.spa
dc.relation.referencesQiu D, Wang Q, Wang H, Xie Q, Zang G, Jiang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011;54:340spa
dc.relation.referencesMuñoz-Espinosa L, Alarcon G, Mercado-Moreira A, Cordero P, Caballero E, Avalos V, et al. Performance of the international classifications criteria for autoinmune hepatitis diagnosis in Mexican patients. Autoimmunity 2011;44:543–548spa
dc.relation.referencesMuratori P, Granito A, Pappas G, Muratori L. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatol Baltim Md 2009;49:1782–1783.spa
dc.relation.referencesVergani D, Alvarez F, Bianchi FB, Cançado ELR, Mackay IR, Manns MP, et al. Liver autoimmune serology: a consensus statement from the committee for autoinmune serology of the international autoimmune hepatitis group. J Hepatol 2004;41:677–683.spa
dc.relation.referencesSerrano-Osuna R, López-López RM, Brito-Zurita OR, Sabag-Ruiz E, Pérez-Fernández H, Ornelas-Aguirre JM. Seroprevalence of antinuclear antibodies in blood donors in the Yaqui Valley. Cir Cir 2014;82:619–627.spa
dc.relation.referencesBogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009;29:241–253.spa
dc.relation.referencesLiberal R, Mieli-Vergani G, Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmun 2013;46:17–24spa
dc.relation.referencesGregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and nonorgan specific autoantibody titres and IgG levels as markers of disease activity: alongitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35:515–519spa
dc.relation.referencesCzaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001;120:239–249.spa
dc.relation.referencesWashington MK, Manns MP: Autoimmune hepatitis; in Burt AD, Portmann B, Ferrel L(eds): MacSween’s Pathology of the Liver. Edinburgh, Churchill Livingstone, 2012;467– 490spa
dc.relation.referencesde Boer YS, van Nieuwkerk CM, Witte BI, Mulder CJ, Bouma G, Bloemena E: Assessment of the histopathological key features in autoimmune hepatitis. Histopathology 2015;66:351–362.spa
dc.relation.referencesHofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E: Centrilobular necrosis in autoinmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59:246–249.spa
dc.relation.referencesMiyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Kobashi H, Sakaguchi K, Shiratori Y: Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007;37:801–805.spa
dc.relation.referencesGaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ: Hepatic granulomas: a 10 year single centre experience. J Clin Pathol 2003;56:850–853.spa
dc.relation.referencesBatts KP, Ludwig J: Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409–1417.spa
dc.relation.referencesScheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372–374.spa
dc.relation.referencesIntraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group. Hepatology 1994;20:15–20.spa
dc.relation.referencesIshak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al: Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699spa
dc.relation.referencesBoberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374.spa
dc.relation.referencesChazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28:296spa
dc.relation.referencesKuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010; 8:530spa
dc.relation.referencesHeneghan, Michael A, MD, MMedSc, FRCPI. Autoimmune hepatitis: Clinical manifestations and diagnosis. UpToDate 2017.spa
dc.relation.referencesBoberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23:1369spa
dc.relation.referencesLudwig J, Batts KP. Histopathology of autoimmune liver disease. In: Autoimmune Liver Diseases, 2d ed, Amsterdam. Krawitt EL, Wiesner RH, Nishioka M (Eds), Elsevier Scien ce Publisher, 1998spa
dc.relation.referencesPerrillo RP, Mason AL, Jacob S, Gerber MA. Hepatitis and cholestasis in a middle-aged woman. Hepatology 1996; 24:730spa
dc.relation.referencesGleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011;60:611-1629spa
dc.relation.referencesLiberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther 2017;45:723-732spa
dc.relation.referencesHeneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-591.spa
dc.relation.referencesZachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011;55:636-646spa
dc.relation.referencesKanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001;39:339-341, 344-348.spa
dc.relation.referencesJames S. Dooley et al. Sherlock’s diseases of the liver and biliary system. 12th ed. WileyBlackwell A John Wiley & Sons, Ltd., Publication. 2011spa
dc.relation.references. Czaja AJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Elsevier Health 2015, 1493-1511.eng
dc.relation.referencesJason W. Wen, Michael A. Kohn, et al. Hospitalizations for autoinmune hepatitis disproportionately affect black and latino americans. Am J Gastroenterol 2018; 113: 243- 253.eng
dc.relation.referencesSebode, M., Hartl, J., Vergani, D., y Lohse, AW. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver international. 2018;38:15- 22.eng
dc.relation.referencesSchmeltzer, PA, y Russo, MW. Clinical narrative: hepatitis autoinmune. The American Journal of Gastroenterology. 2018;113:951–958eng
dc.relation.referencesWebb, GJ, Rana, A., Hodson, J., Akhtar, MZ, Ferguson, JW, Neuberger, et al. Twentyyear comparative analysis of patients with autoinmune liver disease on transplant waitlist. Clinical Gastroenterology abd Hepatology 2018;16:278-287eng
dc.relation.referencesDhruv Lowe, Savio John. Autoimmune hepatitis: Appraisal of current treatment guidelines. World J Hepatol. 2018;10(12):911-923.eng
dc.relation.referencesMieli-Vergani, G., Vergani, D., Czaja, A. J., Manns, M. P., at el. Autoimmune hepatitis. Nature Reviews Disease Primers. 2018;4: 18017.1-17eng
dc.relation.referencesAl-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. Journal Hepatol. 2008;48(1):140-147.eng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subjectHepatitisspa
dc.subjectAnticuerposspa
dc.subjectEnfermosspa
dc.subject.lembHepatitis -- Investigaciones -- Caribe (Región, Colombia)spa
dc.subject.lembGammaglobulinasspa
dc.subject.lembAnticuerposspa
dc.subject.proposalHepatitis autoinmunespa
dc.subject.proposalGammaglobulinaspa
dc.subject.proposalAnticuerposspa
dc.subject.proposalHepatitis de interfasespa
dc.subject.subjectenglishAutoimmune hepatitisspa
dc.subject.subjectenglishGamma globulinspa
dc.subject.subjectenglishAntibodiesspa
dc.subject.subjectenglishInterface hepatitisspa
dc.titleCaracterización clínica de pacientes con Hepatitis autoinmune atendidos en una institución de salud de la Región Caribe colombianaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localTesis de Especializaciónspa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1140815780.pdf
Tamaño:
1.04 MB
Formato:
Adobe Portable Document Format
Descripción:
Trabajo de grado

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción: